K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
--
Prev. Close
--
Prev. Day's Range
--
52W Range
--
Trading Volume
--
MC
--
P/E Ratio
--
EPS
--
Company Overview
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative treatments for serious diseases, particularly in the oncology space. The company is advancing its proprietary drug candidates through comprehensive clinical trials, addressing significant unmet medical needs to enhance patient outcomes. With a focus on building a robust pipeline of transformative therapeutic solutions, Actuate is positioned to drive strategic growth and deliver substantial value to its investors, solidifying its competitive edge within the biotechnology industry.
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters1751 RIVER RUN, FORT WORTH, TX, UNITED STATES, 76107
CountryUSA
Listing Date--
Fiscal Year Ended--
Shares Outstanding--
CIK Code--
Official Website--
Financial Metrics
Indicator
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Income
$0
$0
$0
$0
Operating Expenses
--
--
--
--
Net Income
-$5.626M
-$4.554M
-$5.407M
-$5.949M
Net Profit Margin
--
--
--
--
Earnings Per Share
$-0.24
$-0.20
$-0.25
$-0.30
EBITDA
-$5.621M
-$4.548M
-$5.402M
-$5.944M
Effective Tax Rate
--
-0.0%
--
--
FAQ
ACTU operates in the technology sector, specializing in software development for supply chain optimization and logistics management. The company provides solutions that help businesses streamline operations, reduce costs, and enhance efficiency. ACTU serves industries such as manufacturing, retail, and transportation.
ACTU generates revenue primarily through subscription-based software licenses and consulting services. Its customers rely on ACTU’s platforms for supply chain analytics and integration with existing enterprise systems, driving consistent demand for its products and services in a growing industry.
ACTU competitors include companies like SAP, Oracle, and Manhattan Associates, which also offer supply chain management and logistics software solutions. However, ACTU differentiates itself by focusing on customization and niche markets, appealing to businesses with unique needs.
Currently, ACTU does not pay a dividend, focusing instead on reinvesting its earnings into research and development to expand its technology portfolio and capture further market share. Investors should evaluate the company's growth strategy as part of their assessment.
ACTU's growth opportunities include increasing demand for advanced supply chain analytics, ongoing global digitization trends, and potential geographical expansion into emerging markets. However, market competition and economic challenges could pose risks to sustained growth.
Risks for ACTU include high competition in the technology sector, potential disruptions in global supply chains, and reliance on a subscription revenue model. Additionally, macroeconomic factors such as inflation or economic downturns could impact customer spending on software solutions.
ACTU’s valuation should be assessed relative to competitors like SAP and Oracle, as well as the broader software sector. Analysts often consider metrics like price-to-earnings (P/E) ratios, revenue growth rates, and profitability margins to evaluate whether ACTU is overvalued or undervalued.
Key financial metrics for evaluating ACTU include revenue growth, profit margins, recurring subscription revenue, and operating expenses. Investors should monitor these indicators along with market share trends and R&D spending to understand the company’s financial health and strategic outlook.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
